Radius Health, Inc. (RDUS) VP Brent Hatzis-Schoch Purchases 1,778 Shares of Stock
Radius Health, Inc. (NASDAQ:RDUS) VP Brent Hatzis-Schoch purchased 1,778 shares of Radius Health stock in a transaction on Friday, November 10th. The stock was bought at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the transaction, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Radius Health, Inc. (NASDAQ RDUS) opened at $27.71 on Tuesday. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health, Inc. has a 12-month low of $27.16 and a 12-month high of $55.97.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the previous year, the business earned ($1.07) earnings per share. research analysts predict that Radius Health, Inc. will post -5.4 earnings per share for the current year.
A number of equities research analysts have issued reports on RDUS shares. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research report on Friday, November 3rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a research report on Friday, October 6th. Finally, Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $51.00.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its position in shares of Radius Health by 28.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 180,901 shares of the biopharmaceutical company’s stock worth $6,974,000 after acquiring an additional 40,006 shares in the last quarter. American International Group Inc. raised its position in shares of Radius Health by 8.1% during the 3rd quarter. American International Group Inc. now owns 24,949 shares of the biopharmaceutical company’s stock worth $962,000 after acquiring an additional 1,866 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Radius Health by 184.6% during the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after buying an additional 1,044,615 shares during the period. ING Groep NV acquired a new position in Radius Health during the third quarter worth approximately $2,236,000. Finally, Russell Investments Group Ltd. increased its position in Radius Health by 50.6% during the third quarter. Russell Investments Group Ltd. now owns 18,916 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 6,354 shares during the period.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.